These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 14962253)
21. Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins. Grdisa M Croat Med J; 2004 Apr; 45(2):136-41. PubMed ID: 15103748 [TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283 [TBL] [Abstract][Full Text] [Related]
23. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Giralt S Semin Oncol; 2006 Apr; 33(2 Suppl 5):S36-43. PubMed ID: 16720202 [TBL] [Abstract][Full Text] [Related]
24. T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Chakrabarti S; MacDonald D; Hale G; Holder K; Turner V; Czarnecka H; Thompson J; Fegan C; Waldmann H; Milligan DW Br J Haematol; 2003 Apr; 121(1):109-18. PubMed ID: 12670340 [TBL] [Abstract][Full Text] [Related]
25. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. Robak T Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872 [TBL] [Abstract][Full Text] [Related]
26. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Mehta J; Powles R; Singhal S; Iveson T; Treleaven J; Catovsky D Bone Marrow Transplant; 1996 Mar; 17(3):371-5. PubMed ID: 8704689 [TBL] [Abstract][Full Text] [Related]
28. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Matthews K; Lim Z; Pearce L; Pagliuca A; Alejandro Madrigal J; Mufti GJ; Barber LD Br J Haematol; 2010 Jun; 149(6):879-89. PubMed ID: 20346011 [TBL] [Abstract][Full Text] [Related]
29. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Montillo M; Schinkoethe T; Elter T Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656 [TBL] [Abstract][Full Text] [Related]
30. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]